Vedanta swings to black with Q2 profit at Rs 5,603 crore, revenue down 3.6% YoY

Vedanta Limited on Friday released its fiscal second quarter earnings report with profit at Rs 5,603 crore in comparison to a loss of Rs 915 crore posted during the corresponding quarter of FY24. It reported revenue from operations at Rs 37,171 crore, down 3.6 per cent as against Rs 38,546 crore during the second quarter of previous financial year. The mining major’s EBITDA stood at Rs 9,828 crore, down 14.4 per cent on-year, majorly due to favourable output commodity prices, structural cost saving initiatives and increased premia across businesses.

Ajay Goel, CFO, Vedanta Limited, said, “This has been an outstanding quarter, highlighted by significant progress in our corporate and strategic initiatives, strong financial results, and excellent operational performance. We delivered our highest-ever H1 EBITDA of Rs 20,639 crore, up 46 per cent YoY, with a robust 34 per cent EBITDA margin and PAT before exceptional items of Rs 4,467 crore, a 230 per cent YoY increase. This strong performance is driven by cost efficiency, volume growth, and favourable commodity prices. 

Additionally, he added that the company has raised $1.4 billion at Vedanta through a $1 billion QIP and a $400 million HZL OFS. At the same time, with the $1.2 billion VRL bond issuance and ongoing deleveraging, Vedanta has reduced Holdco debt to $4.8 billion, the lowest level in a decade. 

The second quarter depreciation & amortization stood at Rs 2,696 crore, up 2 per cent YoY mainly in Oil & Gas and increased capitalization at Aluminium.

 » Read More

Related Articles

How will markets open today? Here are top 7 cues to watch ahead of trading on February 11

GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 are implied to open on a higher note on Tuesday. Also, Asian markets opened majorly on a higher note in early trade hours as investors looked past the tariff threats from Donald Trump. Previously, on Monday, the NSE Nifty 50 finished the

Stocks To Watch: Reliance Ind, Grasim Ind, Bata, Titan, ONGC, IHCL, Nykaa, Lupin, Eicher Motors, Ahoka Buildcon

GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 may see a higher opening on Tuesday. Here’s a look at the key stocks to watch in trade. Stocks in Focus: Here’s a comprehensive list of stocks to keep in mind before you start your day. From Reliance Industries to Ashoka Buildcon

DIIs place big bets on 2 pharma giants. Multibaggers in the making?

By Suhel Khan As the world’s largest supplier of generic drugs, renowned for its cost-effective vaccines and generic medicines, India plays a very important role in global medicine. The Indian pharmaceutical industry has transformed into a flourishing sector, currently ranking third globally in terms of production volume and 14th in terms of value. Over the

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

How will markets open today? Here are top 7 cues to watch ahead of trading on February 11

GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 are implied to open on a higher note on Tuesday. Also, Asian markets opened majorly on a higher note in early trade hours as investors looked past the tariff threats from Donald Trump. Previously, on Monday, the NSE Nifty 50 finished the

Stocks To Watch: Reliance Ind, Grasim Ind, Bata, Titan, ONGC, IHCL, Nykaa, Lupin, Eicher Motors, Ahoka Buildcon

GIFT Nifty indicated that Indian equity indices BSE Sensex and NSE Nifty 50 may see a higher opening on Tuesday. Here’s a look at the key stocks to watch in trade. Stocks in Focus: Here’s a comprehensive list of stocks to keep in mind before you start your day. From Reliance Industries to Ashoka Buildcon

DIIs place big bets on 2 pharma giants. Multibaggers in the making?

By Suhel Khan As the world’s largest supplier of generic drugs, renowned for its cost-effective vaccines and generic medicines, India plays a very important role in global medicine. The Indian pharmaceutical industry has transformed into a flourishing sector, currently ranking third globally in terms of production volume and 14th in terms of value. Over the

Rupee fall hurts India Inc hard

The rupee inched closer to the 88-mark against the US dollar on Monday, putting companies in import-sensitive sectors on the edge. While firms fear a surge in imported inflation on account of rupee depreciation, consumer electronics companies, for instance, are taking price hikes to protect margins. In sectors such as thermal power, where the cost

Bata India Q3 profit grows marginally to Rs 58.6 crore on weak demand

Footwear major Bata India on Monday reported a marginal 1% growth in its net profit at Rs 58.6 crore during the October-December quarter, as compared to Rs 57.9 crore in the same quarter in 2023-24. Bloomberg consensus estimates had pegged the net profit during the quarter at Rs 72 crore.  The company’s revenue from operations